Tue, Sep 16, 2014, 2:52 PM EDT - U.S. Markets close in 1 hr 8 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • greenshotshut greenshotshut Oct 8, 2012 2:59 PM Flag

    Telk is the next SNSS

    Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

    Financials

    The company reported the second-quarter financial results on August 10 with the following highlights:
    Revenue $0
    Net loss $2.1 million
    Cash $8.1 million
    Debt $0
    Net cash $8.1 million
    Shares outstanding 1.8 million
    Net cash per share $4.50

    Ongoing Clinical Trials

    TELINTRA Tablets (Ezatiostat HCl, TLK199)

    Phase 2 Trial in Myelodysplastic Syndrome
    Phase 2 Trial in Severe Chronic Neutropenia
    Phase 1 Combination Trial with Revlimid in Myelodysplastic Syndrome

    TELCYTA (canfosfamide, TLK286)

    Phase 2 trial using TELCYTA in MCL, DLBCL & MM

    My analysis

    The stock is currently trading at 70% discount to its net cash per share value. I would recommend buying the shares below the net cash level. I am not expecting the company to be profitable for the full-year 2012.

    Sentiment: Strong Buy

 
SNSS
6.885-0.115(-1.64%)2:52 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.